Twist Bioscience Corporation (TWST)
Market Cap | 1.95B |
Revenue (ttm) | 347.68M |
Net Income (ttm) | -191.15M |
Shares Out | 59.92M |
EPS (ttm) | -3.25 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,051,607 |
Open | 32.45 |
Previous Close | 32.78 |
Day's Range | 31.85 - 33.58 |
52-Week Range | 29.76 - 60.90 |
Beta | 2.54 |
Analysts | Buy |
Price Target | 49.10 (+50.57%) |
Earnings Date | May 5, 2025 |
About TWST
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and ... [Read more]
Financial Performance
In 2024, Twist Bioscience's revenue was $312.97 million, an increase of 27.69% compared to the previous year's $245.11 million. Losses were -$208.73 million, 2.01% more than in 2023.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for TWST stock is "Buy." The 12-month stock price forecast is $49.1, which is an increase of 50.57% from the latest price.
News

Twist Bioscience and Ginkgo Bioworks Revise Collaboration
SOUTH SAN FRANCISCO, Calif. & BOSTON--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care secto...

Twist Bioscience: Expansion Efforts Continue To Face Challenges
Twist Bioscience reported solid results in Q2, but management's downbeat tone on the earnings call suggest there are challenges ahead. Twist has also spun-out its data storage business, which will hel...

Twist Bioscience Corporation (TWST) Q2 2025 Earnings Call Transcript
Twist Bioscience Corporation (NASDAQ:TWST) Q2 2025 Earnings Conference Call April 5, 2025 8:00 AM ET Company Participants Angela Bitting - Senior Vice President of Corporate Affairs Emily Leproust - ...

Twist Bioscience Announces Fiscal 2025 Second Quarter Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today ...

Twist Bioscience Spins Out DNA Data Storage as Independent Company
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today ...

Twist Bioscience Q2 Earnings Preview: Innovative Products, Not Enough Buyers
Twist Bioscience has shown revenue growth from $54.4m in 2019 to potentially >$300m in 2024, but continues to post losses. Despite a diverse customer base and innovative synthetic DNA technology, Twis...

Twist Bioscience Expands Universal Adapter Portfolio with Launch of High Throughput UDI Adapter System
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Expands Universal Adapter Portfolio with Launch of High Throughput UDI Adapter System.

Twist Bioscience and Curio Genomics Collaborate to Accelerate and Streamline NGS Adoption in Agrigenomics
SOUTH SAN FRANCISCO, Calif. & ANN ARBOR, Mich.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health ...

Twist Bioscience Offers Clonal Genes for Global Academic Researchers at Express Speed for No Extra Cost
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today ...

Twist Bioscience to Present at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today ...

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a core mid-cap growth and val...

Twist Bioscience: Valuation Is Weighing On The Stock
Twist Bioscience reported solid Q1 FY25 results, although this was insufficient to drive the company's share price higher. The demand environment remains challenging, and Trump's election has created ...

Twist Bioscience Corporation (TWST) Q1 2025 Earnings Call Transcript
Twist Bioscience Corporation (NASDAQ:TWST) Q1 2025 Earnings Conference Call February 3, 2025 8:00 AM ET Company Participants Angela Bitting - Senior Vice President of Corporate Affairs Emily Leproust...

Twist Bioscience Announces Fiscal 2025 First Quarter Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today ...

Gene Synthesis Market Size to Surpass USD 9.54 Billion by 2033 | Straits Research
The global gene synthesis market size was valued at USD 2.20 billion in 2024 and is projected to reach from USD 2.55 billion in 2025 to USD 9.54 billion by 2033, growing at a CAGR of 15.8% during the ...

Twist Bioscience to Report Fiscal 2025 First Quarter Financial Results on Monday, February 3, 2025
SOUTH SAN FRANCISCO--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announce...

Twist Bioscience to Present at 43rd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announce...

Twist Bioscience: Path To Profitability Beginning To Take Shape
Twist Bioscience's SynBio and NGS segments continue to generate strong growth, despite macro challenges. The prospects of the biopharma segment are uncertain, highlighted by the sale of milestones and...

Twist Bioscience: A Post-Earnings Assessment
Twist Biosciences just posted a solid Q4, which had the stock rising in trading Monday. However, despite impressive sales growth, Twist Biosciences remains unprofitable, with projected losses for seve...

Twist Bioscience's Q4 Earnings And Q1 Guidance Surpass Expectations, Stock Jumps
On Monday, Twist Bioscience Corporation TWST reported a fourth-quarter loss per share of 59 cents, beating the consensus loss of 70 cents.

Twist Bioscience Corporation (TWST) Q4 2024 Earnings Call Transcript
Twist Bioscience Corporation (NASDAQ:TWST) Q4 2024 Earnings Conference Call November 18, 2024 8:00 AM ET Company Participants Angela Bitting - SVP, Corporate Affairs Emily Leproust - CEO and Co-Found...

Twist Bioscience Announces Fiscal 2024 Fourth Quarter and Full Year Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today ...

Twist Bioscience to Present at 7th Annual Evercore HealthCONx Conference
SOUTH SAN FRANCISCO--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform...

Twist Bioscience's Earnings Preview: Partnerships And Valuation Make It A 'Buy'
Since I last covered it, Twist Bioscience has made significant strides. They have secured new partnerships, launched innovative products, and secured strategic financial agreements. TWST's valuation m...

Twist Bioscience Launches FlexPrep™ Ultra-High Throughput Library Preparation Kit for Applications in Agrigenomics and Population Genomics
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...